12 Health Care Stocks Moving In Thursday's Intraday Session

Benzinga · 3d ago
Gainers
- Kodiak Sciences (NASDAQ:KOD) stock rose 66.3% to $37.83 during Thursday's regular session. The market value of their outstanding shares is at $1.3 billion.
- Lunai Bioworks (NASDAQ:LNAI) stock increased by 56.71% to $0.63. The market value of their outstanding shares is at $9.7 million.
- Firefly Neuroscience (NASDAQ:AIFF) stock increased by 54.18% to $2.59. The market value of their outstanding shares is at $26.3 million.
- Precigen (NASDAQ:PGEN) shares increased by 28.22% to $3.98. The market value of their outstanding shares is at $1.0 billion. The company's, Q4 earnings came out yesterday.
- SeaStar Medical Holding (NASDAQ:ICU) stock rose 22.36% to $2.79. The company's market cap stands at $8.6 million. The company's, Q4 earnings came out yesterday.
- ENDRA Life Sciences (NASDAQ:NDRA) shares moved upwards by 20.0% to $4.5. The company's market cap stands at $4.3 million.
Losers
- WAVE Life Sciences (NASDAQ:WVE) shares fell 51.3% to $5.99 during Thursday's regular session. The company's market cap stands at $2.2 billion.
- Icecure Medical (NASDAQ:ICCM) shares decreased by 28.53% to $0.42. The company's market cap stands at $43.0 million.
- Cibus (NASDAQ:CBUS) stock decreased by 27.71% to $2.08. The market value of their outstanding shares is at $198.5 million.
- Artelo Biosciences (NASDAQ:ARTL) shares declined by 26.81% to $3.55. The company's market cap stands at $3.5 million.
- Pulmatrix (NASDAQ:PULM) stock declined by 25.71% to $1.57. The market value of their outstanding shares is at $7.7 million.
- Journey Medical (NASDAQ:DERM) stock fell 23.58% to $5.22. The market value of their outstanding shares is at $227.1 million. As per the news, the Q4 earnings report came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.